ICE Pharma, known as "The Bile Acids Expert," is a multinational company operating in the pharmaceutical and healthcare markets. With a history spanning over 70 years, the company has established a global presence with manufacturing facilities and subsidiaries across North and South America, Europe, Asia, and Oceania, serving customers in over 50 countries. ICE Pharma is a prominent supplier to the pharmaceutical industry, specializing in active pharmaceutical ingredients (APIs) such as Ursodeoxycholic acid (UDCA) and Inosine Pranobex, alongside excipients, cell culture media, GMP intermediates, and research chemicals. Additionally, the company offers contract manufacturing for solid and liquid finished dosage forms, and commercializes branded products in the pharmaceutical, nutraceutical, and cosmetics markets. The company's diverse portfolio spans across the manufacturing, pharmaceutical, and wellness beauty industries, positioning it as an influential player in these sectors. Despite the absence of recent investment data, ICE Pharma's extensive product range, global reach, and longstanding presence make it an intriguing prospect for potential investors seeking opportunities in the pharmaceutical and healthcare arenas.
There is no investment information
No recent news or press coverage available for ICE Pharma.